이식편대숙주병(GvHD) 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 질환 유형별, 제품별, 유통 채널별, 지역별 부문, 경쟁(2020-2030년)
Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Product, By Distribution Channel, By Region and Competition, 2020-2030F
이식편대숙주병(GvHD) 치료 세계 시장 규모는 2024년 29억 4,000만 달러로 평가되었고, 예측 기간 동안 7.34%의 연평균 복합 성장률(CAGR)로 2030년에는 38억 달러에 달할 것으로 예상됩니다.
이식편대숙주병(GvHD)은 줄기세포 및 골수 이식 후 발생할 수 있는 심각한 질환으로, 공여자의 면역세포가 수혜자의 건강한 조직을 공격하여 다양한 합병증을 유발하는 질환입니다. 의료진과 환자들은 GVHD와 그 위험요인, 증상에 대한 인식이 높아지고 있습니다. 이러한 인식 증가는 GVHD의 심각성을 줄이는 데 중요한 조기 진단과 조기 개입으로 이어지고 있습니다. 백혈병 림프종 협회는 2024년에는 62,770명이 백혈병 진단을 받을 것으로 예측했습니다. 조기 진단이 보편화됨에 따라 신속하고 효과적인 GVHD 치료에 대한 수요가 증가하고 있으며, GVHD 치료 시장은 이 질환을 관리하거나 예방하기 위한 의약품 및 치료법에 초점을 맞추었습니다. 이식 센터의 확대는 기존 헬스케어 시장뿐만 아니라 신흥 지역으로까지 확대되고 있습니다. 신흥국에서는 이식센터를 포함한 헬스케어 인프라에 대한 투자가 증가하고 있습니다. 이러한 세계 확대는 이식 대상 환자층을 확대하고, 그 결과 국내외를 막론하고 GVHD 치료 수요를 견인하고 있습니다. 줄기세포 이식의 보급이 진행됨에 따라 GVHD 치료 분야의 연구개발에도 큰 박차를 가하고 있습니다. 제약회사와 연구기관들은 GVHD를 표적으로 삼아 치료하기 위해 특별히 고안된 단클론항체, 면역조절제, 세포치료제 등 새로운 치료법 개발에 적극 나서고 있습니다. 이러한 발전은 의료진의 무기를 강화하여 보다 맞춤화되고 효과적인 치료 옵션을 제공할 수 있도록 돕고 있습니다. 규제 당국도 GVHD 대응의 중요성을 인식하고 있으며, GVHD 치료제의 개발 및 승인을 지원하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
29억 4,000만 달러 |
| 시장 규모 : 2030년 |
38억 달러 |
| CAGR : 2025-2030년 |
7.34% |
| 급성장 부문 |
온라인 약국 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
줄기세포 이식 보급률 상승
주요 시장 이슈
높은 치료비
주요 시장 동향
인식과 진단 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 이식편대숙주병(GvHD) 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 질환 유형별(급성 이식편대숙주병(GvHD), 만성 이식편대숙주병(GvHD))
- 제품별(코르티코스테로이드, 단일클론항체, 티로신키나아제 억제제)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 이식편대숙주병(GvHD) 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 이식편대숙주병(GvHD) 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 이식편대숙주병(GvHD) 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 이식편대숙주병(GvHD) 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 이식편대숙주병(GvHD) 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
- 인수합병(M&A)(해당하는 경우)
- 제품 발매(해당하는 경우)
- 최근 동향
제13장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제14장 경쟁 구도
- Pfizer Inc
- Sanofi SA
- Astellas Pharma Inc
- Incyte Corporation
- Abbvie Inc
- Bristol-Myers Squibb Company
- F Hoffmann-La Roche Ltd
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
Global Graft Versus Host Disease Treatment Market was valued at USD 2.94 Billion in 2024 and is expected to reach USD 3.80 Billion by 2030 with a CAGR of 7.34% during the forecast period. Graft Versus Host Disease (GVHD) is a severe medical condition that can occur after a stem cell or bone marrow transplant. In GVHD, the donor's immune cells attack the recipient's healthy tissues, leading to various complications. Medical professionals and patients are becoming more aware of GVHD, its risk factors, and its symptoms. This heightened awareness is leading to earlier diagnosis and intervention, which can be critical in mitigating the severity of GVHD. The Leukemia and Lymphoma Society projects that 62,770 individuals will be diagnosed with leukemia in 2024. As early diagnosis becomes more commonplace, the demand for prompt and effective GVHD treatments is growing. The GVHD Treatment Market focuses on pharmaceuticals and therapies aimed at managing or preventing this condition. The expansion of transplant centers is not limited to established healthcare markets but extends to emerging regions as well. Developing countries are increasingly investing in healthcare infrastructure, including transplant centers. This global expansion broadens the patient base eligible for transplantation and subsequently drives the demand for GVHD treatment, both locally and internationally. The increasing prevalence of stem cell transplants has spurred significant research and development efforts in the field of GVHD treatment. Pharmaceutical companies and research institutions are actively working on novel therapies, including monoclonal antibodies, immune modulators, and cellular therapies, specifically designed to target and treat GVHD. These advancements are enhancing the armamentarium of healthcare providers, enabling them to offer more tailored and effective treatment options. Regulatory agencies are recognizing the importance of addressing GVHD and are providing support for the development and approval of GVHD treatments.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 2.94 Billion |
| Market Size 2030 | USD 3.80 Billion |
| CAGR 2025-2030 | 7.34% |
| Fastest Growing Segment | Online Pharmacies |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of Stem Cell Transplants
The Global Graft Versus Host Disease (GVHD) Treatment Market is experiencing substantial growth, and one of the pivotal factors behind this expansion is the increasing prevalence of stem cell transplants. Stem cell transplantation has emerged as a powerful tool in the treatment of various hematological and immunological disorders. However, along with the rise in transplant procedures, the incidence of GVHD has also surged. Stem cell transplants, which include both autologous (using a patient's own stem cells) and allogeneic (using donor stem cells) procedures, have become a standard treatment option for a range of conditions. This increasing utilization is evident in the treatment of hematological malignancies like leukemia, lymphoma, and myeloma, as well as non-malignant disorders such as aplastic anemia and severe combined immunodeficiency (SCID). As the number of patients undergoing stem cell transplants rises, so does the potential for GVHD development.
Advancements in medical research and technology have expanded the indications for stem cell transplantation. Beyond traditional uses, researchers and clinicians are exploring transplantation for autoimmune diseases, solid organ transplant support, and regenerative medicine applications. This diversification in transplant indications is widening the patient pool at risk of developing GVHD, further driving the demand for effective GVHD treatments. GVHD is a common and potentially life-threatening complication following allogeneic stem cell transplantation. It occurs when the donor's immune cells recognize the recipient's tissues as foreign and launch an immune response, leading to inflammation and tissue damage. Given its prevalence, GVHD remains a significant concern in the transplantation community. Consequently, there is an ongoing need for innovative and effective treatments to manage this condition.
Key Market Challenges
High Treatment Costs
High treatment costs represent one of the most significant barriers in the GVHD treatment market, as patients face substantial financial challenges. The expenses associated with stem cell transplants, immunosuppressive therapies, and novel treatments such as CAR-T cell therapy often reach tens of thousands of dollars, making them unaffordable for many individuals. Stem cell transplants, for example, can cost upwards of $200,000, and even with insurance, out-of-pocket expenses may remain prohibitive. The high costs of these treatments can create disparities in patient access, particularly for those in low-income demographics or regions with limited healthcare coverage. patients who require long-term immunosuppressive therapy to manage GVHD may continue to incur substantial medical bills. These financial barriers can lead to delays or discontinuation of treatment, ultimately affecting patient outcomes. The rising costs of new, cutting-edge therapies may lead to increasing pressure on healthcare systems and insurance providers, forcing difficult decisions on the allocation of resources. As a result, addressing treatment costs through innovative pricing models, increased insurance coverage, or government funding initiatives is essential to ensure that all patients can access timely and effective care without facing financial hardship.
Key Market Trends
Growing Awareness and Diagnosis
The Global Graft Versus Host Disease (GVHD) Treatment Market is experiencing significant growth, and a pivotal driver behind this expansion is the increasing awareness of GVHD and the improved ability to diagnose the condition. GVHD is a complex and potentially life-threatening complication that can occur following stem cell or bone marrow transplantation. One of the key factors driving market growth is the increasing awareness of GVHD among healthcare professionals. For instance, The Leukemia and Lymphoma Society forecasts that new cases of leukemia, lymphoma, and myeloma will represent 9.4% of the estimated 2,001,140 new cancer cases to be diagnosed in the U.S. in 2024. Over the years, there has been a concerted effort to educate clinicians, transplant specialists, and nurses about the risk factors, signs, and symptoms of GVHD. This heightened awareness has led to more accurate and timely diagnosis, ensuring that GVHD patients receive appropriate care promptly.
In addition to healthcare professionals, GVHD awareness initiatives also target patients and their caregivers. Patients and their families are provided with information about the risks associated with transplantation and the potential development of GVHD. Armed with this knowledge, patients can recognize symptoms early, enabling them to seek medical attention quickly. As patient empowerment becomes more common, the demand for effective GVHD treatments rises. Early diagnosis of GVHD is paramount for successful treatment outcomes. With growing awareness, healthcare providers are more likely to suspect GVHD when patients present with specific symptoms, such as skin rashes, gastrointestinal issues, or liver abnormalities. Rapid diagnosis and intervention can prevent the progression of GVHD to severe and life-threatening stages, underscoring the importance of awareness campaigns. In May 2022, Novartis obtained approval from the European Commission (EC) for Jakavi (ruxolitinib) for the treatment of individuals aged 12 years and older who are experiencing acute or chronic GvHD and have not responded adequately to corticosteroids or other systemic treatments.
Key Market Players
- Pfizer Inc
- Sanofi SA
- Astellas Pharma Inc
- Incyte Corporation
- Abbvie Inc
- Bristol-Myers Squibb Company
- F Hoffmann-La Roche Ltd
Report Scope:
In this report, the Global Graft Versus Host Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Graft Versus Host Disease Treatment Market, By Disease Type:
- Acute Graft Versus Host Disease
- Chronic Graft Versus Host Disease
Graft Versus Host Disease Treatment Market, By Product:
- Corticosteroids
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
Graft Versus Host Disease Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Graft Versus Host Disease Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Graft Versus Host Disease Treatment Market.
Available Customizations:
Global Graft Versus Host Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Graft Versus Host Disease Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Disease Type (Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease)
- 5.2.2. By Product (Corticosteroids, Monoclonal Antibodies, Tyrosine Kinase Inhibitors)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Graft Versus Host Disease Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Disease Type
- 6.2.2. By Product
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Graft Versus Host Disease Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Disease Type
- 6.3.1.2.2. By Product
- 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Graft Versus Host Disease Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Disease Type
- 6.3.2.2.2. By Product
- 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Graft Versus Host Disease Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Disease Type
- 6.3.3.2.2. By Product
- 6.3.3.2.3. By Distribution Channel
7. Europe Graft Versus Host Disease Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Disease Type
- 7.2.2. By Product
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Graft Versus Host Disease Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Disease Type
- 7.3.1.2.2. By Product
- 7.3.1.2.3. By Distribution Channel
- 7.3.2. United Kingdom Graft Versus Host Disease Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Disease Type
- 7.3.2.2.2. By Product
- 7.3.2.2.3. By Distribution Channel
- 7.3.3. Italy Graft Versus Host Disease Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Disease Type
- 7.3.3.2.2. By Product
- 7.3.3.2.3. By Distribution Channel
- 7.3.4. France Graft Versus Host Disease Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Disease Type
- 7.3.4.2.2. By Product
- 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Graft Versus Host Disease Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Disease Type
- 7.3.5.2.2. By Product
- 7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Graft Versus Host Disease Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Disease Type
- 8.2.2. By Product
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Graft Versus Host Disease Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Disease Type
- 8.3.1.2.2. By Product
- 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Graft Versus Host Disease Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Disease Type
- 8.3.2.2.2. By Product
- 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Graft Versus Host Disease Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Disease Type
- 8.3.3.2.2. By Product
- 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Graft Versus Host Disease Treatment Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Disease Type
- 8.3.4.2.2. By Product
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Graft Versus Host Disease Treatment Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Disease Type
- 8.3.5.2.2. By Product
- 8.3.5.2.3. By Distribution Channel
9. South America Graft Versus Host Disease Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Disease Type
- 9.2.2. By Product
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Graft Versus Host Disease Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Disease Type
- 9.3.1.2.2. By Product
- 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Graft Versus Host Disease Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Disease Type
- 9.3.2.2.2. By Product
- 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Graft Versus Host Disease Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Disease Type
- 9.3.3.2.2. By Product
- 9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Graft Versus Host Disease Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Disease Type
- 10.2.2. By Product
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Graft Versus Host Disease Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Disease Type
- 10.3.1.2.2. By Product
- 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Graft Versus Host Disease Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Disease Type
- 10.3.2.2.2. By Product
- 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Graft Versus Host Disease Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Disease Type
- 10.3.3.2.2. By Product
- 10.3.3.2.3. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Pfizer Inc
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Sanofi SA
- 14.3. Astellas Pharma Inc
- 14.4. Incyte Corporation
- 14.5. Abbvie Inc
- 14.6. Bristol-Myers Squibb Company
- 14.7. F Hoffmann-La Roche Ltd
15. Strategic Recommendations
16. About Us & Disclaimer
